Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer
Open Access
- 1 July 2010
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 285 (29), 22639-22650
- https://doi.org/10.1074/jbc.m110.125906
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer TherapyMolecular Therapy, 2010
- Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer CellsMolecular Pharmaceutics, 2009
- Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/IrinotecanJournal of Oncology, 2008
- Treatment with imatinib improves drug delivery and efficacy in NSCLC xenograftsBritish Journal of Cancer, 2007
- Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression underK-selection afterMYC andHRAS oncogene activationInternational Journal of Cancer, 2006
- Immunostimulation Mechanism of LPD Nanoparticle as a Vaccine CarrierMolecular Pharmaceutics, 2004
- Impact of the Cyclooxygenase System on Doxorubicin-Induced Functional Multidrug Resistance 1 Overexpression and Doxorubicin Sensitivity in Acute Myeloid Leukemic HL-60 CellsThe Journal of pharmacology and experimental therapeutics, 2004
- Leukemic Cell-Surface CD13/Aminopeptidase N and Resistance to Apoptosis Mediated by Endothelial CellsJNCI Journal of the National Cancer Institute, 2002
- Down-regulation of Intrinsic P-glycoprotein Expression in Multicellular Prostate Tumor Spheroids by Reactive Oxygen SpeciesPublished by Elsevier BV ,2001
- Transport properties of the multidrug resistance‐associated protein (MRP) in human tumour cellsFEBS Letters, 1996